Thermosome
Intravascular drug release.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
€1.9m | Seed | ||
| Total Funding | 000k | ||
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 11483 % | 233 % | (89 %) | - | 89 % | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Dealroom estimates
Related Content
Thermosome is a biotechnology company focused on developing advanced drug candidates using its proprietary drug delivery technology. This technology leverages a novel Mechanism of Action known as intravascular drug release, which is designed to treat localized diseases, particularly locally advanced solid tumors, where traditional systemic drugs fall short. The company's primary market is the oncology sector, targeting neoadjuvant treatment concepts. Thermosome's business model revolves around research and development of these specialized therapeutics, aiming to create significant value for patients by improving drug efficacy and minimizing systemic side effects. Revenue is generated through partnerships, licensing agreements, and potentially direct sales of their developed drug candidates.
Keywords: biotechnology, drug delivery, intravascular release, oncology, localized treatment, solid tumors, neoadjuvant therapy, proprietary technology, R&D, therapeutics.